We are live on ! Find out more
TYRA icon

Tyra Biosciences

117 hedge funds and large institutions have $500M invested in Tyra Biosciences in 2025 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 42 increasing their positions, 31 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

366% more call options, than puts

Call options by funds: $233K | Put options by funds: $50K

35% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 31

25% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 16

4.84% more ownership

Funds ownership: 96.07%100.91% (+4.8%)

4% more funds holding

Funds holding: 113117 (+4)

20% less funds holding in top 10

Funds holding in top 10: 54 (-1)

26% less capital invested

Capital invested by funds: $676M → $500M (-$176M)

Holders
117
Holders Change
+4
Holders Change %
+3.54%
% of All Funds
1.57%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.05%
New
20
Increased
42
Reduced
31
Closed
16
Calls
$233K
Puts
$50K
Net Calls
+$183K
Net Calls Change
+$213K
Name Holding Trade Value Shares
Change
Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$98.9M
CPX
2
Canaan Partners XI
California
$38.5M -$456K -35,267 -0.8%
APMC
3
Alta Partners Management Company
Wyoming
$37.9M
NI
4
Nextech Invest
Switzerland
$37.7M
BI
5
BVF Inc
California
$36.7M
TCM
6
TCG Crossover Management
California
$27M +$11.8M +909,000 +46%
VPC
7
Vestal Point Capital
New York
$26.8M +$24.5M +1,889,829 +191%
Janus Henderson Group
8
Janus Henderson Group
United Kingdom
$26.3M +$12.3M +946,917 +54%
KCM
9
Kynam Capital Management
New Jersey
$22.4M +$24.3M +1,875,589 +354%
O
10
OrbiMed
New York
$16.3M +$3.66M +282,745 +19%
Fidelity Investments
11
Fidelity Investments
Massachusetts
$15.9M -$18.1M -1,400,822 -45%
BlackRock
12
BlackRock
New York
$15.8M -$292K -22,587 -1%
Vanguard Group
13
Vanguard Group
Pennsylvania
$11.3M +$137K +10,606 +0.9%
FCM
14
Farallon Capital Management
California
$10.6M +$1.85M +142,837 +14%
CC
15
Commodore Capital
New York
$8.84M +$12.3M +950,000 New
5VM
16
5AM Venture Management
California
$8.74M
Geode Capital Management
17
Geode Capital Management
Massachusetts
$4.8M -$16.7K -1,288 -0.2%
Pictet Asset Management
18
Pictet Asset Management
Switzerland
$4.27M +$1.36M +105,101 +30%
SCM
19
Sio Capital Management
New York
$3.87M +$2.27M +175,747 +73%
State Street
20
State Street
Massachusetts
$3.85M +$83K +6,415 +2%
Millennium Management
21
Millennium Management
New York
$3.76M +$1.15M +89,024 +28%
Marshall Wace
22
Marshall Wace
United Kingdom
$3.54M +$4.23M +326,623 +604%
Jacobs Levy Equity Management
23
Jacobs Levy Equity Management
New Jersey
$2.81M +$745K +57,556 +24%
Balyasny Asset Management
24
Balyasny Asset Management
Illinois
$2.26M +$3.15M +243,244 New
Northern Trust
25
Northern Trust
Illinois
$2.01M -$81.7K -6,317 -3%

TYRA Hedge Fund Activity: Q1 2025 in Review

117 of the 7,461 institutional investors tracked by Wall St. Rank reported a position in Tyra Biosciences (TYRA) for Q1 2025, worth a combined $500M — down 26% from $676M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new TYRA positions and 16 closed out — a net gain of 4 holders — while 42 added to existing stakes and 31 trimmed.

The largest buyer was Vestal Point Capital, adding an estimated $24.5M. The largest seller was Boxer Capital Management, exiting entirely with an estimated $28.2M sold.

  • 117 institutional investors held Tyra Biosciences (TYRA) as of Q1 2025, up from 113 in Q4 2024.
  • Funds reported $500M of Tyra Biosciences stock for Q1 2025, down 26% quarter-over-quarter.
  • 20 funds opened new Tyra Biosciences positions in Q1 2025 and 16 closed out, a net change of +4 holders.
  • The largest Tyra Biosciences buyer in Q1 2025 was Vestal Point Capital, an estimated $24.5M added.
  • The largest Tyra Biosciences seller in Q1 2025 was Boxer Capital Management, an estimated $28.2M sold.

Based on aggregated 13F filings for Q1 2025.